In August, the U.S. Drug Enforcement Administration upheld the federal monopoly on marijuana for research by denying University of Massachusetts-Amherst professor Lyle Craker, Ph.D., a license to start his own medical marijuana facility.
On September 16, we saw why the federal monopoly needs to end when the Department of Health and Human Services rejected our planned, FDA-reviewed study of marijuana for 50 veterans with posttraumatic stress disorder (PTSD) and refused to sell us the marijuana we require for the study.
In response, we’re taking the DEA to federal court and doing everything we can to remind the public what can happen when science is silenced by politics: studies don’t get started, medicines don’t get made, and patients don’t get treated.
Public support is building fast for psychedelic and medical marijuana research. The Washington Post, The Guardian, Salon, The Huffington Post, and other major media have reported on our international MDMA-assisted psychotherapy research program and the government’s medical marijuana research blockade.
Brad Burge, M.A.
MAPS Director of Communications
